분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-14 17:58:34 , Hit : 1068
 Gilead hepatitis C drug highly effective in cirrhosis patients


Reuters
By Ransdell Pierson
November 11, 2014 11:29 AM


      
By Ransdell Pierson

(Reuters) - Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.

The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians.

The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year.

All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi.

In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks.

Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks.

Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis.

Shares of Gilead were up 1.4 percent at $108.54 in morning trading.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)







827   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1671
826   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1078
825   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1241
824   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1096
823   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1144
822   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1723
821   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1344
820   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1273
819   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1617
818   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1285
817   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1395
816   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1926
815   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1129
814   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1496
813   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1162
812   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1605
811   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1667
810   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1188
  Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1068
808   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1472

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN